Art

J-GLOBAL ID：201702219009639598   Reference number：17A1089746

Pharmacokinetics and the optimal regimen for levofloxacin in critically ill patients receiving continuous hemodiafiltration

持続血液濾過透析中の重症患者におけるレボフロキサシンの薬物動態と最適な投与計画

Author (13)： WADA Takeshi (Hokkaido Univ. Graduate School of Medicine, Sapporo, JPN) ,  KOBAYASHI Masaki (Hokkaido Univ., Sapporo, JPN) ,  ONO Yuichi (Hokkaido Univ. Graduate School of Medicine, Sapporo, JPN) ,  MIZUGAKI Asumi (Hokkaido Univ. Graduate School of Medicine, Sapporo, JPN) ,  KATABAMI Kenichi (Hokkaido Univ. Graduate School of Medicine, Sapporo, JPN) ,  MAEKAWA Kunihiko (Hokkaido Univ. Graduate School of Medicine, Sapporo, JPN) ,  MIYAMOTO Daisuke (Hokkaido Univ. Graduate School of Medicine, Sapporo, JPN) ,  YANAGIDA Yuichiro (Hokkaido Univ. Graduate School of Medicine, Sapporo, JPN) ,  HAYAKAWA Mineji (Hokkaido Univ. Graduate School of Medicine, Sapporo, JPN) ,  SAWAMURA Atsushi (Hokkaido Univ. Graduate School of Medicine, Sapporo, JPN) ,  ISEKI Ken (Hokkaido Univ., Sapporo, JPN) ,  ISEKI Ken (Hokkaido Univ. Hospital, Sapporo, JPN) ,  GANDO Satoshi (Hokkaido Univ. Graduate School of Medicine, Sapporo, JPN)
Material： Journal of Intensive Care (Web)
Volume： 3  Issue： May  Page： 3:22 (WEB ONLY)  Publication year： May. 2015 
JST Material Number： U1116A  ISSN： 2052-0492  Document type： Article
Article type： 短報  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Thesaurus term： *hemodialysis ,...
Semi thesaurus term： acute kidney damage ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A1089746&from=J-GLOBAL&jstjournalNo=U1116A") }}

JST classification (4)： Treatment for infectious diseases,parasitic diseases.  (GD01030D) ,  Clinical application of antibacterial drugs  (GW17030D) ,  Clinical biopharmacy  (GY01022L) ,  Other therapies for urogenital diseases  (GM05040R)

Substance index (1)： Levofloxacin

Reference (7)：

• Tanigawara Y, Nomura H, Kagimoto N, Okumura K, Hori R. Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases. Biol Pharm Bull. 1995;18:315-20.
• Nightingale CH, Grant EM, Quintiliani R. Pharmacodynamics and pharmacokinetics of levofloxacin. Chemotherapy. 2000;46 Suppl 1:6-14.
• Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect. 2001;7:589-96.
• Dalhoff A, Schmitz FJ. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol Infect Dis. 2003;22:203-21.
• Rebuck JA, Fish DN, Abraham E. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Pharmacotherapy. 2002;22:1216-25.

Terms in the title (5)： 持続血液濾過透析 ,  重症患者 ,  レボフロキサシン ,  薬物動態 ,  投与計画